Beyond Air, INC 8-K filings

Beyond Air announced a private placement raising approximately $10.2 million in gross proceeds, with potential for up to $30.1 million, to fund working capital and the commercial launch of its LungFit PH device.

Beyond Air, Inc. announced a 1-for-20 reverse stock split to regain compliance with Nasdaq listing rules.

Beyond Air reported 107% annual revenue growth to $7.7 million and announced a transition to a December 31st fiscal year-end.

Beyond Air has been granted a conditional extension by the Nasdaq Hearings Panel to regain compliance with the bid price rule by July 31, 2026, with a potential reverse stock split on the horizon.

Beyond Air has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting notice regarding its failure to maintain a $1.00 minimum bid price.

Beyond Air, Inc. reported a 105% year-over-year revenue increase to $2.2 million for its fiscal third quarter, alongside strategic corporate updates and an extended cash runway into 2027.

Beyond Air, Inc. announced the results of its 2026 Annual Meeting, where stockholders elected six directors, ratified its accounting firm, and approved an increase in shares for its equity incentive plan.

Beyond Air, Inc. announced a $5.0 million private placement of common stock and warrants to an institutional investor, priced at-the-market under Nasdaq rules.

XTL Biopharmaceuticals has acquired an 85% stake in Beyond Air's NeuroNOS subsidiary, gaining a foothold in the autism therapeutics market with Nobel Prize-winning scientific leadership.

Beyond Air, Inc. announced the appointment of Daniel Moorhead as its new Chief Financial Officer, effective January 5, 2026.

Beyond Air, Inc. announced the appointment of Denton Duke Dewrell as its new principal financial officer and principal accounting officer, effective December 8, 2025.

Beyond Air, Inc. announced the resignation of Chief Financial Officer Doug Larson, effective December 5, 2025, with Duke Drewell stepping in as interim CFO.

Beyond Air, Inc. announced fiscal second quarter 2026 financial results, reporting a 128% year-over-year revenue increase to $1.8 million and securing $32 million in new financing.

Beyond Air, Inc. announced new financing agreements totaling up to $32 million, including a $12 million secured promissory note and a $20 million equity line of credit, extending its cash runway into 2027.

Beyond Air, Inc. announced the immediate exercise of existing common stock warrants, generating approximately $3.18 million in gross proceeds, and the issuance of new unregistered warrants.

NeuroNOS, a Beyond Air subsidiary, has received U.S. FDA Orphan Drug Designation for its investigational therapy BA-101 to treat Glioblastoma.

Beyond Air, Inc. reported a 157% increase in fiscal first-quarter revenue to $1.8 million, driven by strong LungFit PH adoption and international expansion, while reaffirming full-year fiscal 2026 revenue guidance.

Beyond Air, Inc. has approved and filed a 1-for-20 reverse stock split of its common stock, effective July 14, 2025, to raise its per share bid price above $1.00 and regain compliance with Nasdaq listing rules.

Beyond Air, Inc. announced that its stockholders have approved a proposal granting the Board of Directors the authority to effect a reverse stock split of the company's common stock within the next year.

Beyond Air, Inc. announced a 220% increase in fiscal year 2025 revenue, provided robust fiscal year 2026 guidance, and submitted a premarket approval supplement for its next-generation LungFit PH II device to the FDA, alongside significant international expansion and a new board appointment.

NeuroNOS, a subsidiary of Beyond Air, has secured $2 million in initial funding to advance the preclinical development of its innovative autism therapy.

Beyond Air announces expansion of its LungFit PH distribution network to include France, Romania, Turkey, and Morocco, bringing the total to 18 countries.

Beyond Air, Inc. has entered into an agreement with BTIG, LLC to sell up to $35 million of its common stock through an at-the-market equity offering.

Beyond Air announces a 34% revenue increase compared to the previous quarter and the receipt of CE Mark for LungFit PH in Europe.

Beyond Air has been granted an additional 180-day extension by Nasdaq to regain compliance with the minimum bid price rule.

Beyond Air, Inc. has dismissed Marcum LLP as its independent auditor and appointed WithumSmith+Brown, PC, effective December 17, 2024.

Beyond Cancer, Ltd. has received approval from the Israeli Ministry of Health to begin a Phase 1b clinical trial of its Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) therapy in combination with anti-PD-1 therapy for solid tumor cancers.

Beyond Air has received European CE mark approval for its LungFit PH system, allowing sales in the EU and other regions and triggering a $1 million milestone payment.

Beyond Air's stockholders approved an increase in authorized shares and a repricing of stock options at the 2025 Annual Meeting.

Beyond Air announced a 17% revenue increase compared to the previous quarter, secured $20.6 million in funding, and extended its cash runway through June 2026.